Fine-Tuning the Angiogenic Response to Vascular Endothelial Growth Factor

James K. Liao

Vascular endothelial growth factor (VEGF) is an important mediator of vascular development and postnatal angiogenesis. Homozygous deletion of VEGF gene leads to impaired vascular formation and early embryonic lethality. Interestingly, deletion of just one VEGF allele is sufficient to produce similar vascular abnormalities, suggesting that the strength and integrity of the VEGF signaling pathway are critical for the spatial–temporal formation of blood vessels in utero. These actions of VEGF are mediated predominantly by two tyrosine kinase receptors: VEGFR-1 (flt-1) and VEGFR-2 (flk-1/KDR). Mice with homozygous mutations that inactivate either receptor die in utero with a similar phenotype to mice with VEGF deletion, indicating that both receptors are obligatory for the function of VEGF. Although the vascular phenotype between these VEGFR mutant mice are overlapping to some degree, they do differ in terms of showing that VEGFR-2 plays a greater role in vascular organization, whereas VEGFR-1 appears to be more important in mediating hemangioblast commitment and endothelial cell replication. Nevertheless, both VEGFR-1 and VEGFR-2 are essential in coordinating endothelial cell assembly and vascular formation during embryonic development.

The upregulation of VEGF is also necessary for physiological and pathological neovascularization in response to hypoxia and for tumor growth. The precise role of VEGFR-1 and VEGFR-2 in mediating the postnatal angiogenic response to VEGF, however, is less well understood and, in some cases, somewhat controversial. For example, mouse models with the VEGFR-1 allele are allelically impaired, indicating that both receptors are necessary for the angiogenic response to VEGF. Nevertheless, although VEGFR-1 and VEGFR-2 in mice exhibit normal vascular development and angiogenic response, the authors hypothesize that excessive activation of Akt via VEGFR-2 may be responsible for the impaired angiogenic response to VEGF. To further define the mechanism underlying the potential cross-talk between VEGFR-1 and VEGFR-2 in ischemia- or VEGF-induced angiogenesis, Nishi et al., in this issue of Circulation Research, investigated the role of VEGFR-1 in endothelial cell culture in vitro using small interfering RNA approach and in vivo using heterozygous VEGFR-1-/- mice subjected to hindlimb ischemia. They found that angiogenesis and blood flow recovery was mildly impaired in VEGFR-1-/- mice compared to wild-type (WT) littermates, despite comparable protein expression of VEGF and VEGFR-2 in both groups of mice. Surprisingly, phosphorylation of Akt was higher in the aorta of VEGFR-1-/- mice, and this finding was confirmed in vitro when VEGFR-1 was knocked down in endothelial cells using retroviral small interfering RNA for VEGFR-1 but not VEGFR-2. Interestingly, the phosphorylation of endothelial NO synthase (eNOS) was higher, but cGMP level was lower in VEGFR-1 knockout endothelial cells, suggesting decreased NO bioavailability. Unfortunately, eNOS activity and NO production were not directly measured in these cells, and additional studies were not performed with NO donors or eNOS inhibitors. These studies would have been interesting and could have provided further insights into the mechanism involved because eNOS is an important downstream mediator of ischemia-induced angiogenesis.

To further define the mechanism underlying the potential cross-talk between VEGFR-1 and VEGFR-2 in ischemia- or VEGF-induced angiogenesis, Nishi et al., in this issue of Circulation Research, investigated the role of VEGFR-1 in endothelial cell culture in vitro using small interfering RNA approach and in vivo using heterozygous VEGFR-1-/- mice subjected to hindlimb ischemia. They found that angiogenesis and blood flow recovery was mildly impaired in VEGFR-1-/- mice compared to wild-type (WT) littermates, despite comparable protein expression of VEGF and VEGFR-2 in both groups of mice. Surprisingly, phosphorylation of Akt was higher in the aorta of VEGFR-1-/- mice, and this finding was confirmed in vitro when VEGFR-1 was knocked down in endothelial cells using retroviral small interfering RNA for VEGFR-1 but not VEGFR-2. Interestingly, the phosphorylation of endothelial NO synthase (eNOS) was higher, but cGMP level was lower in VEGFR-1 knockout endothelial cells, suggesting decreased NO bioavailability. Unfortunately, eNOS activity and NO production were not directly measured in these cells, and additional studies were not performed with NO donors or eNOS inhibitors. These studies would have been interesting and could have provided further insights into the mechanism involved because eNOS is an important downstream mediator of ischemia-induced angiogenesis.

The authors hypothesize that excessive activation of Akt via VEGFR-2 may be responsible for the impaired angiogenic response in VEGFR-1-/- mice. To test this, they generated double heterozygous VEGFR-1-/- VEGFR-2-/- mutant mice and showed that the impaired angiogenic response to hindlimb ischemia was restored to a level that was comparable to what was observed in WT mice. These findings are consistent with a previous study showing that Akt1-/- mice have increased vascular permeability and augmented angiogenic response. Interestingly, Akt1-/- mice in this study did not show a greater angiogenic response to hindlimb ischemia compared to WT mice, despite having lower levels of phosphorylated Akt. This is puzzling and somewhat contradictory to the hypothesis of the authors. Perhaps, there is a threshold level of phosphorylated Akt that is required for
enhancing angiogenesis. Nevertheless, the authors conclude that VEGFR-1 facilitates ischemia-induced angiogenesis by fine-tuning and preventing excessive Akt activation by VEGF through VEGFR-2. Whether this modulation of VEGFR-2 signaling is attributable to a direct crosstalk or an indirect decay effect of VEGFR-1 remains to be determined. These findings, therefore, underscore the importance of having just the right amount of VEGF signaling at the right time, when deficient or excessive Akt activation via VEGFR-2 could lead to impaired angiogenic response to VEGF.

In agreement with the notion that excessive Akt activation mitigates the angiogenic response to VEGF, the authors have previously shown that Akt increases senescence, negatively regulates endothelial cell lifespan, and inhibits endothelial tubular formation via a p53/p21-dependent pathway.20 These findings, however, appear to be contradictory to other studies showing that Akt1 is critical for ischemia-induced and VEGF-mediated angiogenesis.21 Perhaps, the discrepancies showing that Akt1 is critical for ischemia-induced and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001;7:575–583.


As the study by Nishi et al17 has demonstrated, having too much Akt activation may not necessary be beneficial. The precise mechanisms of how Akt activation is regulated under physiological and pathological conditions still requires further investigation, but, perhaps, VEGFR-1 could serve as an important factor that balances and fine-tunes the angiogenic response to VEGF.

Sources of Funding
This work was supported by NIH grants HL052233 and HL080187.

Disclosures
None.

References


Key Words: VEGF • angiogenesis • protein kinase Akt • ischemia
Fine-Tuning the Angiogenic Response to Vascular Endothelial Growth Factor
James K. Liao

Circ Res. 2008;103:229-230
doi: 10.1161/CIRCRESAHA.108.181628
Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/103/3/229

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org//subscriptions/